Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
Una Kjällquist(Karolinska Institutet), Johan Hartman(Karolinska University Hospital), Balázs Ács(Karolinska University Hospital), Scarlett Garcia Hernandez(Saint Göran Hospital), Emelié Karlsson(Karolinska Institutet), Alexios Matikas(Karolinska University Hospital), Erik Olsson(Uppsala University), Theodoros Foukakis(Karolinska Institutet), Henrik Lindman(Uppsala University), Christine Lundgren(Linköping University), Luisa Edman Kessler(Karolinska Institutet), Sara Margolin(University of Copenhagen), Maria Ekholm
Cited by 21
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Artificial intelligence as the next step towards precision pathology
|Journal of Internal Medicine|2020|443